专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP4444328A1 FULL LIGHT REPAIR 审中-实审
公开(公告)号：EP4444328A1
公开(公告)日：2024-10-16
申请号：EP22847082.9
申请日：2022-12-08
申请人： Coty Inc.
发明人： DOUCET, Olivier , CHAMAYOU-ROBERT, Cécile , PUJOS, Muriel
IPC分类号： A61K35/612 , A61K35/68 , A61K35/74 , A61K36/02 , A61K36/31 , A61K38/51 , A61K8/9706 , A61K8/9789 , A61Q17/04 , A61Q19/08 , A61P17/18 , A61K31/198
CPC分类号： A61Q17/04 , A61K2800/592220130101 , A61K8/9789 , A61K8/9706 , A61K36/31 , A61K36/02 , A61K35/74 , A61Q19/08 , A61K35/612 , A61K35/68 , A61K38/51 , C12Y401/99003 , A61P17/18 , A61K31/198

3. 发明公开

EP3501532A2 THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF 审中-公开
公开(公告)号：EP3501532A2
公开(公告)日：2019-06-26
申请号：EP18210159.2
申请日：2015-05-27
申请人： Stealth BioTherapeutics Corp
发明人： WILSON, D. Travis
IPC分类号： A61K38/07 , A61K31/353
CPC分类号： A61K38/10 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/08 , A61K38/13 , A61K38/1709 , A61K38/40 , A61K38/44 , A61K38/443 , A61K38/45 , A61K38/46 , A61K38/51 , A61K38/53 , A61K47/645 , C07K5/06078 , C07K5/06095 , C07K5/06156 , C07K5/0812 , C07K5/0815 , C07K5/0817 , C07K5/0821 , C07K5/1016 , C07K5/1021 , C12Y101/01037 , C12Y101/01042 , C12Y102/04002 , C12Y103/05001 , C12Y106/05003 , C12Y109/03001 , C12Y110/02002 , C12Y203/03001 , C12Y306/03014 , C12Y402/01002 , C12Y402/01003 , C12Y602/01004 , C12Y604/01001
摘要： Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents ( e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'-dimethyl-Tyr-D-Arg-Phe-Lys-NH 2 , Phe-D-Arg-Phe-Lys-NH 2 , or D-Arg-2',6'-Dmt-Lys-Phe-NH 2 .

4. 发明公开

EP3479842A2 PROKARYOTIC PHENYLALANINE AMMONIA-LYASES AND THEIR USE FOR TREATING PHENYLKETONURIA AND HYPERPHENYLALANINEMIA 审中-公开
公开(公告)号：EP3479842A2
公开(公告)日：2019-05-08
申请号：EP18187522.0
申请日：2011-02-03
申请人： BioMarin Pharmaceutical Inc.
发明人： KAKKIS, Emil, D. , VELLARD, Michel Claude , WENDT, Daniel, J. , MUTHALIF, Mubarack , OKHAMAFE, Augustus O. , BELL, Sean M. , ZECHERLE, G. Nick , ANTONSEN, Kris , ZHANG, Yanhong , LY, Kieu Y. , FITZPATRICK, Paul A.
IPC分类号： A61K38/51 , C12N9/88 , A61P3/00 , A61K9/00 , C07K1/14 , A61K47/60
CPC分类号： C12N9/88 , A61K9/0019 , A61K38/51 , A61K47/60 , C07K1/14 , C12Y403/01024
摘要： Provided are compositions comprising a recombinant phenylalanine ammonia-lyase (PAL) derived from the bacterial species Anabaena variabilis, Nostoc punctiforme, Streptomyces maritimus, Streptomyces verticillatus, Soragium cellulosum, Nostoc tobacum, or Pseudomonas putida, or a biologically active fragment, mutant, variant or analog thereof, and a pharmaceutically acceptable carrier. Further provided are such compositions of recombinant bacterial PAL and biologically active fragments, mutants, variants or analogs thereof for use in treating phenylketonuria hyperphenylalaninemia.

5. 发明授权

EP2508200B8 CARBONIC ANHYDRASE I SERVING AS NOVEL ANTIGEN TO BE USED FOR TREATMENT OF AUTOIMMUNE DISEASES 有权转让
标题翻译：碳酸酐酶I作为新型抗原用于治疗自身免疫性疾病
公开(公告)号：EP2508200B8
公开(公告)日：2018-05-02
申请号：EP10824620.8
申请日：2010-10-07
申请人： Hiasa, Yoichi
发明人： MURAKAMI, Hidehiro , YAMANISHI, Hirofumi , ONJI, Morikazu
IPC分类号： A61K39/00 , A61K35/12 , A61K35/28 , A61K38/51 , A61P1/04 , A61P37/06 , A61P43/00 , C12N5/0783 , C12N9/88 , C12N15/09
CPC分类号： A61K38/51 , A61K39/0008 , A61K2039/5154 , A61K2039/5158 , C12N9/88 , C12Y402/01001
摘要： The purpose of the present invention is to provide a method for treating autoimmune diseases. Disclosed is a method or the like for the treatment of autoimmune diseases, which utilizes an antigen-specific tolerogenic antigen presenting cell. Specifically disclosed are: a method for producing an antigen-specific tolerogenic antigen presenting cell, which is characterized by using carbonic anhydrase I; an immunogenic antigen presenting cell which is specific to carbonic anhydrase I; and a method or the like for the treatment of autoimmune diseases (especially inflammatory bowel diseases), which is characterized by using a tolerogenic antigen presenting cell which is specific to carbonic anhydrase I.

6. 发明公开

EP3312275A1 BROAD SPECTRUM OF STREPTOCOCCUS LYASE AND USE THEREOF 有权转让
标题翻译：广谱链球菌LYASE及其用途
公开(公告)号：EP3312275A1
公开(公告)日：2018-04-25
申请号：EP16779579.8
申请日：2016-04-12
申请人： Wuhan Phagelux Bio-Tech Company Limited
发明人： WEI, Hongping , YANG, Hang , WANG, Jing , YU, Junping
IPC分类号： C12N9/88 , C12N15/60 , A61K38/51 , A61P31/04 , A61P1/02
CPC分类号： A61K38/51 , A61P31/04 , C12N9/88 , C12N15/101 , C12N15/70
摘要： This invention discloses a lysin that can kill many species of Streptococci. A new lysin, ClyR, was constructed by the gene splicing method. The ClyR can effectively kill different species of Streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus suis, Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus mutans, Streptococcus equi, and various Enterococci and Staphylococcus aureus. ClyR shows good stability and is not sensitive to EDTA and high concentration of NaCl. Moreover, the ClyR is active in a wide range of pH and maintains high activity in pH 5-11. Recombinant protein ClyR is well expressed in E. coli stain BL21 (DE3). High doses of ClyR showed no apparent toxicity in mice. Furthermore, administration of 0.8 mg per mouse once is able to completely protect the mouse infected with lethal doses of Group B Streptococci. The ClyR can be used alone or in combination with different forms of reagents and solutions, for the control of a variety of Streptococci and for the treatment of infections caused by these bacteria. It has a broad application prospect.
摘要翻译：本发明公开了可杀死许多种链球菌的溶素。通过基因剪接方法构建新的溶素ClyR。 ClyR可以有效地杀死不同种类的链球菌，包括肺炎链球菌，化脓链球菌，猪链球菌，乳房链球菌，无乳链球菌，停乳链球菌，变形链球菌，马链球菌，以及各种肠球菌和金黄色葡萄球菌。 ClyR表现出良好的稳定性，对EDTA和高浓度NaCl不敏感。此外，ClyR在很宽的pH范围内具有活性，并在pH 5-11中保持高活性。重组蛋白ClyR在大肠杆菌染色BL21（DE3）中很好地表达。高剂量的ClyR显示在小鼠中没有明显的毒性。此外，每只小鼠施用0.8mg能够完全保护用致死剂量的B组链球菌感染的小鼠。 ClyR可单独使用或与不同形式的试剂和溶液联合使用，用于控制各种链球菌以及治疗由这些细菌引起的感染。具有广阔的应用前景。

7. 发明公开

EP3166972A4 ANTIBODIES TO ARGININOSUCCINATE SYNTHASE AND RELATED METHODS 有权
公开(公告)号：EP3166972A4
公开(公告)日：2018-01-31
申请号：EP15819121
申请日：2015-07-08
申请人： TDW GROUP
发明人： HE WEI , GUO YUNYUN , WU BOR-WEN
IPC分类号： C07K16/18 , A61K38/45 , A61K38/50 , A61K38/51 , A61K39/395 , A61K49/16 , A61K51/10 , C07K16/40 , C12N9/00 , C12N9/78 , G01N33/573 , G01N33/574
CPC分类号： C07K16/40 , A61K38/45 , A61K38/50 , A61K38/51 , C07K2317/20 , C07K2317/565 , C07K2317/76 , C12N9/78 , C12Y207/00 , C12Y207/03003 , C12Y305/03006 , C12Y401/01019 , G01N33/573 , G01N33/57496 , G01N2333/9015 , G01N2800/52
摘要： Antibodies, and antigen-binding fragments, which specifically bind to argininosuccinate synthase, and related compositions, kits, and methods of use, which are useful as companion diagnostics to identify suitable subjects for arginine deprivation or depletion therapies such as ADI-PEG 20 and other arginine deiminase (ADI) polypeptide-based therapies.

8. 发明公开

EP3148557A4 USE OF ALLENE OXIDE SYNTHASE FOR SEMEN PRESERVATION AND ASSISTED REPRODUCTION 无效
公开(公告)号：EP3148557A4
公开(公告)日：2017-12-27
申请号：EP15799445
申请日：2015-05-27
申请人： PACIFIC BRANDS
发明人： BACKHAUS RALPH ANDREW , HODGKINSON STEVEN CHARLES
IPC分类号： C12N9/88 , A61K35/00 , A61K35/52 , A61K38/00 , A61K38/43
CPC分类号： A01N1/0226 , A01N1/0284 , A61D19/02 , A61K35/52 , A61K36/28 , A61K38/51 , C12N5/061 , C12N9/88 , C12N2501/73 , C12Y402/01 , C12Y402/01092
摘要： The use of allene oxide synthase as a preservative for semen particularly for use in assisted reproductive procedures for humans and in the breeding of cattle horses and other animals.

9. 发明公开

EP3094341A4 ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF 有权
公开(公告)号：EP3094341A4
公开(公告)日：2017-11-01
申请号：EP15735001
申请日：2015-01-13
申请人： BERG LLC , UNIV MIAMI
发明人： NARAIN NIVEN RAJIN , SARANGARAJAN RANGAPRASAD , VISHNUDAS VIVEK K , GESTA STEPHANE , JING ENXUAN , DAUNERT SYLVIA , DEO SAPNA K , JIMENEZ JOAQUIN JUAN , DIKICI EMRE , DAFTARIAN PIROUZ MOHAMMAD
IPC分类号： A61P3/08 , A61K38/28 , A61K38/46 , A61P3/10 , C07K1/00 , C12N15/00
CPC分类号： A61K38/51 , A61K9/0019 , A61K9/0053 , A61K38/00 , A61K47/48246 , A61K47/59 , A61K47/64 , A61K49/0008 , C12N9/88 , C12Q1/54 , C12Y402/01011 , G01N2333/988 , G01N2800/042
摘要： The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

10. 发明公开

EP3211084A1 PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS 失效
标题翻译：蛋白多糖降解突变体治疗中枢神经系统
公开(公告)号：EP3211084A1
公开(公告)日：2017-08-30
申请号：EP17164947.8
申请日：2004-05-17
申请人： Acorda Therapeutics, Inc.
发明人： GRUSKIN, Elliott. A. , CAGGIANO, Anthony. O. , ROY, Gargi , D'SOUZA, Rohini
IPC分类号： C12N15/60 , C12N15/63 , A61K48/00 , C12N9/88 , A61K38/51 , A61K38/00 , A61K35/30 , C07K14/005 , C07K19/00 , C12N9/26
CPC分类号： C12N9/88 , A61K35/30 , A61K38/00 , A61K38/51 , A61K45/06 , C07K14/005 , C07K19/00 , C07K2319/00 , C07K2319/03 , C07K2319/10 , C12N9/2408 , C12Y302/01035 , C12Y302/01036 , C12Y402/02001 , C12Y402/02004 , C12Y402/02005
摘要： The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system ("CNS") injury or disease.
摘要翻译：本公开涉及软骨素酶蛋白质的制备和缺失突变体及其在促进治疗组合物扩散到组织中的方法中的用途以及它们在中枢神经系统（“CNS”）损伤或疾病后用于神经功能恢复的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式